Filtern
Volltext vorhanden
- ja (1)
Gehört zur Bibliographie
- ja (1) (entfernen)
Erscheinungsjahr
- 2015 (1)
Dokumenttyp
Sprache
- Englisch (1) (entfernen)
Schlagworte
- CXCR4 (1)
- CXCR4/SDF-1 (1)
- FDG PET/CT (1)
- autologous transplantation (1)
- bone disease (1)
- cancer (1)
- cells (1)
- chemokine receptor (1)
- in vivo imaging (1)
- involvement (1)
- malignancies (1)
- microenvironment (1)
- multiple myeloma (1)
- positron emission tomography (1)
- survival (1)
Institut
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (1) (entfernen)
CXCR4 is a G-protein-coupled receptor that mediates recruitment of blood cells toward its ligand SDF-1. In cancer, high CXCR4 expression is frequently associated with tumor dissemination andpoor prognosis. We evaluated the novel CXCR4 probe [\(^{68}\)Ga]Pentixafor for invivo mapping of CXCR4 expression density in mice xenografted with human CXCR4-positive MM cell lines and patients with advanced MM by means of positron emission tomography (PET). [\(^{68}\)Ga]Pentixafor PET provided images with excellent specificity and contrast. In 10 of 14 patients with advanced MM [\(^{68}\)Ga]Pentixafor PET/CT scans revealed MM manifestations, whereas only nine of 14 standard [\(^{18}\)F]fluorodeoxyglucose PET/CT scans were rated visually positive. Assessment of blood counts and standard CD34\(^{+}\) flow cytometry did not reveal significant blood count changes associated with tracer application. Based on these highly encouraging data on clinical PET imaging of CXCR4 expression in a cohort of MM patients, we conclude that [\(^{68}\)Ga]Pentixafor PET opens a broad field for clinical investigations on CXCR4 expression and for CXCR4-directed therapeutic approaches in MM and other diseases.